0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letter |

Discoid and Subacute Lupus Erythematosus Treated With 0.5% R-Salbutamol Cream FREE

Hans Christian Wulf, MD, DSc; Susanne Ullman, MD
Arch Dermatol. 2007;143(12):1589-1603. doi:10.1001/archderm.143.12.1589.
Text Size: A A A
Published online

Treatment of discoid lupus erythematosus (DLE) and subacute lupus erythematosus (SCLE) includes topical or systemic glucocorticosteroid, chloroquine, methotrexate, retinoids, and even thalidomide.1 In severe cases, these treatments may be ineffective or not well tolerated leading to cessation of therapy or lack of compliance. Alternative treatments to modify the autoimmune response in the skin would therefore be useful.1,2

We investigated the effect of ASF-1096 (Astion Pharma, Copenhagen, Denmark) in an explorative study. The active substance is a sulfate salt of R-salbutamol in 0.5% concentration in an oil-in-water emulsion. R-Salbutamol has various anti-inflammatory effects and inhibits proliferation and secretion of IL-2 and interferon γ in human T cells stimulated with phytohemagglutinin.2 Furthermore, R-salbutamol inhibits superoxide generation and peroxidase release from stimulated human granulocytes.3,4 These effects might have therapeutic potential in cutaneous lupus.

Nine consecutive patients entered this prospective explorative investigation, 5 with treatment-resistant DLE and 4 with SCLE. Patients were asked to discontinue treatment with topical glucocorticosteroid and use R-salbutamol cream twice daily on affected skin areas or parts thereof. Photographic documentation was performed before and during treatment. The patients were seen every 2 to 3 weeks. The treatment efficacy was evaluated by the physician using assessment of symptoms and disease grade. The physician graded the effect of the treatment on a 4-point scale: 0, no effect; +, slight improvement; ++, some improvement; and +++, pronounced effect. The adverse effect of dermatitis was graded in the same way (Table).

Table Graphic Jump LocationTable. Results of Treatment With 0.5% R-Salbutamol Cream (RSC)

Results and patient data are listed in the Table. Images of patients before and after treatment are presented in the Figure.

Place holder to copy figure label and caption
Figure.

Subacute lupus erythematosus (SCLE) (A-C) and discoid lupus erythematosus (DLE) (D). A-C, Patient with SCLE before and after 2 to 4 weeks of twice-daily treatment with ASF-1096 (Astion Pharma, Copenhagen, Denmark). D, Patient with DLE before and after 11 months of twice-daily treatment with ASF-1096.

Graphic Jump Location

The 4 patients treated for SCLE all responded within a few days and had pronounced effect after 2 to 3 weeks. After “healing,” some patients reported that the skin reaction could change from day to day from totally cleared to slightly erythematous. After each application, some patients experienced diminished itch within minutes and complete relief from itch after a few days (Table).

After experiencing a primary beneficial effect, 2 of the patients developed an adverse event in the form of dermatitis in parts of the treated area, one in the face and the other on the back. This reaction started after 4 to 6 weeks of use and after the full effect had been obtained. The dermatitis ceased within 4 to 6 days of topical glucocorticosteroid application, leaving no flare in the lupus. Thereafter, treatment was resumed in 1 of the patients using a different cream vehicle, which was tolerated.

The 5 patients with DLE underwent treatment on hypertrophic lesions as well as relatively new and nonhypertrophic lesions. Some minor effect was seen on the hypertrophic elements beginning after 2 months of treatment (Figure, D). The relatively new and nonhypertrophic lesions responded well but to a lesser degree than the SCLE. Two patients reported excellent effect, while 2 others reported no effect. However, 1 of the latter had bad compliance.

The skin lesions fluctuated in severity over time, especially in SCLE. We can assume that these fluctuations were not related to the time of year because treatment was initiated at different times of the year. The fluctuations give a risk of bias; however, the effect of the treatment on new and nonhypertrophic lesions was very fast and was sustained during the treatment period, though without 100% clearance (Table). Old hypertrophic lesions are difficult to treat, and it was therefore positive to see a slow improvement over time even in these cases.

When salbutamol is used in a powder formulation for inhalation in patients with asthma, irritation of the mucosa is a known adverse effect, as are tremor and tachycardia.5 It was therefore interesting to notice that a dermatitis could be seen after dermal application as well, although different vehicle formulations were involved. Contact allergy could not be anticipated, since the dermatitis when present was not seen in all the treated areas, and the drug was reapplied without recurrence of the dermatitis in 1 of the patients. Even when treating areas up to 2000 cm2 twice daily, no signs of tremor or tachycardia were observed. No other adverse effects were reported.

An explorative investigation does not have the proper controls used in a controlled clinical trial. However, the results from this investigation seem very promising.

ARTICLE INFORMATION

Correspondence: Dr Wulf, Department of Dermatology, Copenhagen University Hospital, Bispebjerg Bakke 23, 2400 Copenhagen NV, Denmark (hcw01@bbh.regionh.dk).

Financial Disclosure: Dr Wulf is member of the advisory board of Astion Pharma.

Kuhn  AedLehmann  PedRuzicka  Ted Cutaneous Lupus Erythematosus.  Berlin and Heidelberg, Germany Springer2005;
Baramki  DKoester  JAnderson  AJBorish  L Modulation of T-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influence of (R)-isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol 2002;109 (3) 449- 454
PubMed Link to Article
Volcheck  GWKelkar  PBartemes  KRGleich  GJKita  H Effects of (R)- and (S)-isomers of β-adrenergic agonists on eosinophil response to interleukin-5. Clin Exp Allergy 2005;35 (10) 1341- 1346
PubMed Link to Article
Leff  ARHerrnreiter  ANaclerio  RMBaroody  FMHandley  DAMuñoz  NM Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils. Pulm Pharmacol Ther 1997;10 (2) 97- 104
PubMed Link to Article
Pinto Pereira  LMClement  YNPereira  SMP Comparison of innovator and generic salbutamol inhalers: a double-blind randomized study of efficacy and tolerance. Int J Clin Pharmacol Res 2002;22 (3-4) 73- 80
PubMed

Figures

Place holder to copy figure label and caption
Figure.

Subacute lupus erythematosus (SCLE) (A-C) and discoid lupus erythematosus (DLE) (D). A-C, Patient with SCLE before and after 2 to 4 weeks of twice-daily treatment with ASF-1096 (Astion Pharma, Copenhagen, Denmark). D, Patient with DLE before and after 11 months of twice-daily treatment with ASF-1096.

Graphic Jump Location

Tables

Table Graphic Jump LocationTable. Results of Treatment With 0.5% R-Salbutamol Cream (RSC)

References

Kuhn  AedLehmann  PedRuzicka  Ted Cutaneous Lupus Erythematosus.  Berlin and Heidelberg, Germany Springer2005;
Baramki  DKoester  JAnderson  AJBorish  L Modulation of T-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influence of (R)-isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol 2002;109 (3) 449- 454
PubMed Link to Article
Volcheck  GWKelkar  PBartemes  KRGleich  GJKita  H Effects of (R)- and (S)-isomers of β-adrenergic agonists on eosinophil response to interleukin-5. Clin Exp Allergy 2005;35 (10) 1341- 1346
PubMed Link to Article
Leff  ARHerrnreiter  ANaclerio  RMBaroody  FMHandley  DAMuñoz  NM Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils. Pulm Pharmacol Ther 1997;10 (2) 97- 104
PubMed Link to Article
Pinto Pereira  LMClement  YNPereira  SMP Comparison of innovator and generic salbutamol inhalers: a double-blind randomized study of efficacy and tolerance. Int J Clin Pharmacol Res 2002;22 (3-4) 73- 80
PubMed

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

647 Views
7 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Jobs